查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2003218

兽用镇静剂市场：2026-2032年全球市场预测（依产品类型、动物类型、应用、通路和最终用户划分）

Animal Sedative Market by Product Type, Animal Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物镇静剂市场价值将达到 2.0656 亿美元，到 2026 年将成长到 2.2344 亿美元，到 2032 年将达到 3.1427 亿美元，复合年增长率为 6.17%。

主要市场统计数据
基准年 2025 2.0656亿美元
预计年份：2026年 2.2344亿美元
预测年份：2032年 3.1427亿美元
复合年增长率 (%) 6.17%

概述了不断变化的临床需求、监管考虑因素以及製剂技术的进步，这些因素正在重塑兽医学各个方面镇静剂的选择和使用。

随着兽医学的进步与不断变化的临床需求和监管审查相结合，动物镇静疗法的格局正在迅速变化。临床医生越来越需要兼顾疗效和安全性的药物，以适用于不同类型的动物和各种手术；而饲主和医疗机构相关人员则希望获得可预测的行为和生理反应，以支持诊断、手术和日常护理。同时，製剂和给药途径的创新正在为诊所和实践拓展更多实际选择，进一步凸显了实证镇静剂选择和合理使用的重要性。

临床实践的现代化、监管的加强以及数位技术和供应链的创新，是如何共同重新定义兽医镇静剂生产商和诊所的成功因素的？

动物镇静剂市场格局正受到多项变革性变化的影响，这些变化远不止于产品创新。在临床实践中，治疗方案正转向多管齐下，将镇静剂与镇痛药和抗焦虑药联合使用，以在保持疗效的同时最大限度地减少药物剂量，从而提高安全性和恢復率。同时，监管机构对精神药物及其在牲畜体内残留限量的关注度不断提高，迫使生产商优化标籤、制定停药期指南并加强供应链可追溯性，以维持市场准入和临床医生的信任。

本研究评估了关税波动和贸易政策趋势如何影响兽用镇静剂利害关係人的供应链选择、采购行为和长期策略定位。

贸易政策的调整和关税的变化对兽药采购趋势有显着的影响。关税会改变进口总成本，促进本地化生产，并影响品牌药和非专利药的选择，尤其对于用量较大的镇静剂和对温度敏感的镇静剂而言更是如此。当进口关税上涨时，批发商和诊所可能会优先选择国产製剂，或签订长期合约以避免价格波动的影响。这反过来又会影响生产商的市场准入和投资策略。

细分市场洞察揭示了不同的产品类型、动物类型、应用和分销管道如何影响临床选择、商业策略和最终用户期望。

对细分市场的深入理解有助于更透彻地洞察产品性能和商业性机会。产品类型着重于每种给药途径独特的操作特性和临床医生的偏好，例如吸入剂、注射和口服製剂。起效时间、持续时间、给药便利性和监测负担等因素会影响所有医疗机构的临床应用。动物类型也至关重要，因为伴侣动物、马匹和牲畜的治疗需求差异显着，导致製剂、给药指南以及残留和清除方面的考量重点不同，进而影响临床通讯协定设计和监管标籤。

从跨区域观点探讨管理体制、临床实务成熟度和文化态度对美洲、欧洲、中东和非洲以及亚太地区产品策略的影响。

区域趋势持续影响镇静剂的临床实践、法规结构和商业模式。在美洲，成熟的兽医基础设施和强大的私立动物医院网络推动了对先进製剂和兽医服务的需求，而监管监督和相关人员的期望则强调药物安全检测和受管製药物的管理。欧洲、中东和非洲的差异尤其显着。欧洲部分地区严格的法规和动物福利标准与中东和非洲某些司法管辖区新兴市场的需求形成鲜明对比，影响着进入模式、定价策略和临床指南的协调统一进程。

决定镇静剂领域产品差异化和市场进入有效性的关键竞争和合作趋势，涉及製造商、经销商和临床相关人员。

动物镇静剂市场的竞争格局既有老牌动物用药品药厂，也有高度专业化、创新公司。业界领导企业强调完善的临床试验项目、全面的安全性数据和强有力的监管文件，以吸引兽医和机构负责人采用其产品。同时，一些反应敏捷的公司正在开发特色配方、新型给药途径和配套诊断工具，力求透过易用性、安全性和物种特异性来脱颖而出。

製造商、经销商和临床领导者采用的可操作策略重点，专注于证据建构、供应链韧性、监管合作以及针对分销管道优化的商业化。

该领域的领导者应优先考虑平衡策略，将临床证据的累积、监管前瞻性和供应链韧性相结合。投资于严谨的对比研究和真实世界数据能够增强产品价值提案，并促进指南的采纳。同时，积极与监管机构合作，重点关注标籤、肉类残留管理和药品监管合规性，可以降低市场准入风险，增强相关人员的信心。在营运方面，建立多元化的製造地和开发紧急采购系统可以减轻贸易政策变化和关税波动的影响。

该文件清楚地解释了混合方法研究途径，该方法结合了对从业人员的访谈、临床文献、监管审查和交叉检验，以确保研究结果的稳健性和可重复性。

本分析采用混合方法，将一手质性资料与严谨的二手研究结合，以确保全面涵盖并检验的结论。一手研究包括对执业兽医、临床药理学家、分销主管和采购专家进行结构化访谈，以收集关于产品性能、采购限制和不断发展的临床通讯协定的第一手观点。这些发现与同行评审文献、监管指导文件和产品标籤等二级资讯来源进行交叉比对，以检验临床声明和安全性考虑因素。

将策略挑战和实际影响相结合，强调证据一致性、监管准备和分销灵活性是实现永续成功的驱动力。

这些研究结果共同表明，动物镇静剂领域的成功取决于临床疗效、监管合规性和可操作的分销实践之间的协调一致。相关人员必须保持营运弹性，以应对供应链和关税相关的风险，同时也要兼顾物种特异性要求、应用特定绩效预期以及区域性管理体制的差异。将实证实践与临床医生教育和通路特定的商业化策略相结合，对于促进产品渗透和确保长期的临床及商业性永续性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物镇静剂市场：依产品类型划分

  • 吸入剂
  • 注射药物
  • 口服

第九章：动物镇静剂市场：依动物类型划分

  • 伴侣动物
  • 马
  • 家畜

第十章：动物镇静剂市场：依应用领域划分

  • 行为管理
  • 诊断治疗
  • 外科手术

第十一章：动物镇静剂市场：依通路划分

  • 网路药房
  • 零售药房
  • 动物诊所
  • 动物医院

第十二章：动物镇静剂市场：依最终用户划分

  • 研究机构
  • 动物诊所
  • 动物用药品批发商
  • 动物医院

第十三章：动物镇静剂市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：动物镇静剂市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：动物镇静剂市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国兽用镇静剂市场

第十七章：中国动物镇静剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aspen Veterinary Resources, Ltd.
  • Bayer AG
  • Bimeda Holdings PLC
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Dechra Pharmaceuticals PLC
  • Huvepharma EOOD
  • Jurox Pty Ltd.
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Orion Corporation
  • Vetoquinol SA
  • Virbac SA
  • Vetoquinol SA
  • Wildlife Pharmaceuticals, Inc.
  • Zoetis Inc.
Product Code: MRR-8652FEF459B1

The Animal Sedative Market was valued at USD 206.56 million in 2025 and is projected to grow to USD 223.44 million in 2026, with a CAGR of 6.17%, reaching USD 314.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 206.56 million
Estimated Year [2026] USD 223.44 million
Forecast Year [2032] USD 314.27 million
CAGR (%) 6.17%

An overview of changing clinical demands regulatory considerations and formulation advances that are reshaping selection and use of sedative agents across veterinary care settings

The therapeutic and procedural landscape for animal sedatives has evolved rapidly as advances in veterinary practice intersect with shifting clinical expectations and regulatory scrutiny. Clinicians increasingly demand agents that balance efficacy with safety across diverse species and procedures, while owners and institutional stakeholders seek predictable behavioral and physiological responses to support diagnostic, surgical, and routine care. Meanwhile, innovation in formulation and delivery routes has expanded practical options in clinics and field settings, amplifying the importance of evidence-driven selection and stewardship of sedative agents.

Against this backdrop, the industry must reconcile the need for effective sedation protocols with heightened emphasis on animal welfare, drug residue considerations in food-producing species, and the operational imperatives of veterinary service providers. These dynamics are driving a more data-centric approach to product adoption, where comparative performance, handling logistics, and compatibility with multimodal analgesia inform procurement and clinical guidelines. As a result, manufacturers, distributors, and clinical leaders are recalibrating strategies to align with both practitioner preferences and regulatory expectations across markets.

How clinical practice modernization regulatory tightening and digital and supply chain innovations are jointly redefining manufacturer and clinic success factors in veterinary sedation

The market environment for animal sedatives is being reshaped by several transformative shifts that extend beyond simple product innovation. Clinical practice has moved toward multimodal approaches that integrate sedatives with analgesics and anxiolytics to minimize drug doses while preserving efficacy, thereby improving safety margins and recovery profiles. Concurrently, heightened regulatory attention on controlled substances and residue limits in livestock has pressured manufacturers to optimize labeling, withdrawal guidance, and supply chain traceability to maintain market access and clinician confidence.

Technological and operational shifts are also evident. Digital tools for dosing calculations, teleconsultation platforms for remote behavioral assessment, and electronic medical records are enabling more consistent application of sedation protocols and facilitating post-procedure monitoring. In parallel, supply chain modernization-driven by e-commerce channels, integrated distribution partnerships, and temperature-controlled logistics-has altered product availability and the speed of clinical adoption. Taken together, these developments are creating an ecosystem where clinical efficacy, regulatory compliance, and logistical reliability are equally critical for long-term success.

Evaluating how tariff shifts and trade policy developments are influencing supply chain choices procurement behavior and long-term strategic positioning for veterinary sedative stakeholders

Trade policy adjustments and tariff movements have a measurable influence on the procurement dynamics of pharmaceutical supplies used in veterinary practice. Tariffs can change landed costs, incentivize localization of production, and affect the choice between branded and generic products, particularly for high-volume or temperature-sensitive sedatives. When import duties rise, distributors and clinics may prioritize domestically produced formulations or negotiate longer-term contracts to insulate against price volatility, which in turn affects manufacturers' market entry and investment strategies.

In addition, tariff-driven cost pressures often prompt supply chain diversification. Companies may seek alternative sourcing routes, shift manufacturing footprints, or restructure distribution models to maintain margin integrity and ensure continuity of supply. Downstream, veterinary service providers adjust inventory policies and clinical protocols to reflect changes in product availability and cost. These responses emphasize the importance of proactive trade policy monitoring and scenario planning so that stakeholders can mitigate disruption, preserve clinical standards, and sustain access to essential sedative agents across care settings.

Segment-driven insights that clarify how distinct product types animal classes applications and distribution pathways shape clinical choices commercial strategies and end-user expectations

A granular understanding of segmentation deepens insight into product performance and commercial opportunity. Based on Product Type, attention centers on the distinct operational characteristics and clinician preferences for Inhalant, Injectable, and Oral modalities, where considerations such as onset time, duration, ease of administration, and monitoring burden shape clinical adoption across settings. Based on Animal Type, therapeutic demands vary substantially among Companion Animals, Equine, and Livestock, creating divergent priorities in formulation, dosing guidance, and residue or clearance concerns that influence both clinical protocol design and regulatory labeling.

Based on Application, use-case specificity is paramount; Behavioral Management, Diagnostic Procedures, and Surgical Procedures each impose unique efficacy and safety requirements, leading to differentiated product positioning and educational needs. Based on Distribution Channel, the landscape includes Online Pharmacies, Retail Pharmacies, Veterinary Clinics, and Veterinary Hospitals, with Online Pharmacies further delineated into Manufacturer Website and Third-Party Website, and Retail Pharmacies further divided into Chain Pharmacies and Independent Pharmacies, all of which influence purchasing behavior, margin structures, and point-of-care accessibility. Finally, Based on End User, the roles of Research Institutes, Veterinary Clinics, Veterinary Drug Distributors, and Veterinary Hospitals determine demand profiles, procurement cycles, and expectations for technical support and post-sale services.

A cross-regional perspective on how regulatory regimes clinical practice maturity and cultural attitudes across the Americas Europe Middle East & Africa and Asia-Pacific influence product strategies

Regional dynamics continue to shape clinical practice, regulatory frameworks, and commercial models for sedative agents. In the Americas, a mature veterinary infrastructure and strong private clinic networks drive demand for advanced formulations and practice-level services, while regulatory oversight and stakeholder expectations emphasize pharmacovigilance and controlled-substance management. In Europe, Middle East & Africa, heterogeneity is pronounced: regulatory stringency and welfare standards in parts of Europe contrast with developing-market needs across some Middle Eastern and African jurisdictions, which affects access models, pricing strategies, and the pace of clinical guideline harmonization.

In the Asia-Pacific region, rapid expansion of veterinary services, rising pet ownership, and growing investments in livestock production create opportunities for broader adoption of diverse sedative modalities, yet pricing sensitivity and fragmented distribution can limit uptake of higher-cost innovations. Across all regions, local regulatory landscapes, cultural attitudes toward animal care, and the maturity of veterinary education systems play decisive roles in the diffusion of new products and protocols. Consequently, region-specific go-to-market strategies, regulatory engagement plans, and clinician education initiatives are crucial for any organization seeking sustainable presence across these geographies.

Key competitive and partnership trends among manufacturers distributors and clinical stakeholders that are determining product differentiation and go-to-market effectiveness in the sedatives arena

Competitive dynamics in the animal sedative space reflect a mixture of established veterinary pharmaceutical manufacturers and specialized innovators. Industry leaders emphasize robust clinical trial programs, comprehensive safety data, and strong regulatory dossiers to support adoption among veterinarians and institutional purchasers. Concurrently, a cohort of agile players is advancing niche formulations, novel delivery mechanisms, and companion diagnostic tools that aim to differentiate on ease-of-use, safety, and species-specific performance.

Strategic partnerships between manufacturers and distribution networks, as well as alliances with veterinary professional associations and academic centers, are increasingly common to accelerate clinical validation and guideline incorporation. Mergers and selective licensing deals continue to shape the landscape, enabling companies to broaden portfolios and access new geographic channels. For stakeholders, the imperative is to combine scientific rigor with pragmatic commercialization tactics, ensuring that product claims are substantiated, post-market surveillance is robust, and clinician support programs address real-world administration and monitoring challenges.

Actionable strategic priorities for manufacturers distributors and clinical leaders focused on evidence building supply chain resilience regulatory engagement and channel-optimized commercialization

Leaders in the sector should prioritize a balanced agenda that integrates clinical evidence generation, regulatory foresight, and supply chain resilience. Investing in rigorous comparative studies and real-world evidence will strengthen product value propositions and facilitate guideline inclusion. At the same time, proactive regulatory engagement focused on labeling, residue management for food-producing animals, and controlled-substance compliance will reduce market access risk and enhance stakeholder trust. Operationally, establishing diversified manufacturing footprints and contingency sourcing arrangements can mitigate the impact of trade policy changes and tariff volatility.

Commercially, firms should tailor distribution strategies to the channel dynamics identified earlier, ensuring that online and retail pathways complement clinic- and hospital-based access, while providing education and technical support to end users. Collaborative initiatives with veterinary training programs and professional societies can accelerate adoption and standardize protocols. Finally, embedding digital tools for dosing decision support and post-procedure monitoring will improve clinical outcomes and create differentiation, making it easier to demonstrate the practical benefits of specific sedative solutions to both clinicians and institutional purchasers.

A clear explanation of the mixed-methods research approach combining practitioner interviews clinical literature regulatory review and cross-validation to ensure robust and reproducible insights

This analysis synthesizes a mixed-methods approach integrating primary qualitative inputs and rigorous secondary research to ensure comprehensive coverage and verifiable conclusions. Primary research involved structured interviews with practicing veterinarians, clinical pharmacologists, distribution executives, and procurement specialists to capture first-hand perspectives on product performance, procurement constraints, and evolving clinical protocols. These insights were triangulated with secondary sources including peer-reviewed literature, regulatory guidance documents, and product labeling to validate clinical assertions and safety considerations.

Data integrity was reinforced through cross-validation across multiple stakeholder groups and regions, with attention to methodological transparency and reproducibility. Where possible, comparative analyses focused on publicly available clinical data, pharmacokinetic profiles, and regulatory records to support claims about relative advantages and implementation considerations. Limitations include variability in reporting standards across jurisdictions and the evolving nature of regulatory guidance, which the methodology addresses through periodic updates and sensitivity checks to maintain relevance and accuracy over time.

A synthesis of strategic imperatives and practical takeaways that emphasize evidence alignment regulatory preparedness and distribution agility as drivers of durable success

The collective findings underscore a consistent theme: success in the animal sedative domain depends on aligning clinical performance with regulatory compliance and pragmatic distribution practices. Stakeholders must navigate species-specific requirements, application-driven performance expectations, and geographically diverse regulatory regimes while maintaining operational agility that addresses supply chain and tariff-related risks. Integrating evidence generation with clinician education and channel-specific commercialization will be central to driving adoption and ensuring long-term clinical and commercial viability.

Looking ahead, organizations that invest in robust safety and efficacy data, cultivate strategic partnerships across distribution and clinical education networks, and implement flexible supply strategies will be best positioned to respond to changing regulatory and market conditions. In essence, a coordinated approach that marries scientific credibility with practical execution will deliver the greatest benefit to animal health professionals and the animals they serve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Sedative Market, by Product Type

  • 8.1. Inhalant
  • 8.2. Injectable
  • 8.3. Oral

9. Animal Sedative Market, by Animal Type

  • 9.1. Companion Animals
  • 9.2. Equine
  • 9.3. Livestock

10. Animal Sedative Market, by Application

  • 10.1. Behavioral Management
  • 10.2. Diagnostic Procedures
  • 10.3. Surgical Procedures

11. Animal Sedative Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Animal Sedative Market, by End User

  • 12.1. Research Institutes
  • 12.2. Veterinary Clinics
  • 12.3. Veterinary Drug Distributors
  • 12.4. Veterinary Hospitals

13. Animal Sedative Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Sedative Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Sedative Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Animal Sedative Market

17. China Animal Sedative Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Aspen Veterinary Resources, Ltd.
  • 18.6. Bayer AG
  • 18.7. Bimeda Holdings PLC
  • 18.8. Ceva Sante Animale
  • 18.9. Chanelle Pharma Group
  • 18.10. Dechra Pharmaceuticals PLC
  • 18.11. Huvepharma EOOD
  • 18.12. Jurox Pty Ltd.
  • 18.13. Merck & Co., Inc.
  • 18.14. Norbrook Laboratories Limited
  • 18.15. Orion Corporation
  • 18.16. Vetoquinol S.A.
  • 18.17. Virbac SA
  • 18.18. Vetoquinol S.A.
  • 18.19. Wildlife Pharmaceuticals, Inc.
  • 18.20. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL SEDATIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL SEDATIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INHALANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY BEHAVIORAL MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY DRUG DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL SEDATIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ANIMAL SEDATIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ANIMAL SEDATIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ANIMAL SEDATIVE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA ANIMAL SEDATIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA ANIMAL SEDATIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA ANIMAL SEDATIVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)